News

According to the agreement, Pluristem is expected to license worldwide rights to United Therapeutics to develop and commercialize the future product for the treatment of PH, however Pluristem

Earlier in October 2006, Biotica has licensed all rights of rapamycin analogue program to Wyeth Pharmaceuticals, which was acquired by Pfizer in October 2009. Biotica CEO Edward Hodgkin

Both the companies are expected to establish a Product Advisory Committee to manage the activities that are required to develop and seek approval for PCV and to pursue

The application works in conjunction with HP’s global printing partners who are able to print labels in high volumes even when required in some of the world’s most

BioClinica‘s net income was $924,000, compared to $403,000 for the same period in the prior year. The company’s income from operations were $1.48m for the second quarter ended

Upon the development, Aspergillus fungus will be detected using BD MAX Molecular Testing System. Lab21 CEO Graham Mullis said the potential to detect Aspergillus in blood using real-time

The SLIM is a high shear mixer system which uses rotor/stator assembly to generate a powerful vacuum to draw solids into the mix chamber. The liquid stream enters

The new patent covers the methods of using vosaroxin at clinically relevant dose ranges and schedules for leukemia treatment. Sunesis is now recruiting patients for Valor Phase 3

Incyte has also received priority review status for ruxolitinib NDA, which the FDA aims to complete within six months. The NDA submission is supported by the results from